Table 3. Main results of eligible studies evaluating RARβ2 methylation and pathologic stage/Gleason score in prostate cancer.
Variables | pa | OR | 95% CI | Heterogeneity | ||
X2 | P | I2 | ||||
stage | 5 | 0.67 | 0.40–1.08 | 1.75 | 0. 782 | 0.0%b |
Gleason score | 8 | 0. 54 | 0.28–1.04 | 17.91 | 0. 012 | 60. 9% |
Number of comparisons.
Between group heterogeneity not calculated; only valid with inverse variance method.